Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with angiotensin-converting enzyme inhibitors

Kidney and Blood Pressure Research

Volumn 32, Issue 6, 2010, Pages 440-444

  Seeman, Tomáš ^a   Pohl, Michael ^b   Misselwitz, Joachim ^b   John, Ulrike ^b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitors; Chronic kidney disease; Proteinuria

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; POTASSIUM; RAMIPRIL;

ADD ON THERAPY; ADOLESCENT; ARTICLE; BLOOD PRESSURE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; EDEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MALE; ORTHOSTATIC HYPOTENSION; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RASH; SCHOOL CHILD;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD CELL COUNT; BLOOD PRESSURE; CHILD; CHILD, PRESCHOOL; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LOSARTAN; MALE; POTASSIUM; PROTEINURIA;

EID: 72049088306     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000266478     Document Type: Article

References (21)

1. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-1456.
2. Wingen AM, Fabian-Bach C, Schaefer F, Mehls O: Randomised multicentre study of a low-protein diet on the progression of chronic renal failure in children. European Study Group of Nutritional Treatment of Chronic Renal Failure in Childhood. Lancet 1997; 349:1117-1123.
3. Wang S, LaPage J, Hirschberg R: Proteinuria and progression of chronic renal disease. Kidney Blood Press Res 2000;23:167-169.
4. Remuzzi G, Chiurchiu C, Ruggenenti P: Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int 2004;92:S90-S96.
5. Nangaku M, Ohse T, Tanaka T, Kojima I, Fujita T: Renoprotection with anti-hypertensives: reduction of proteinuria and improvement of oxygenation via inhibition of the renin-angiotensin system. Curr Hypert Rev 2005;1:67-76.
6. Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18:44-49.
7. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000; 18:89-95.
8. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124.
9. Butani L: Angiotensin blockade in children with chronic glomerulonephritis and heavy proteinuria. Pediatr Nephrol 2005;20:1651-1654.
10. Litwin M, Grenda R, Sladowska J, Antonie-wicz J: Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol 2006;21:1716-1722.
11. Lubrano R, Soscia F, Elli M, Ventriglia F, Raggi C, Travasso E, Scateni S, Di Maio V, Versacci P, Masciangelo R, Romero S: Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria. Pediatrics 2006;118:e833-e838.
12. Chandar J, Abitbol C, Montané B, Zilleruelo G: Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Nephrol Dial Transplant 2007;22:1332-1337.
13. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration to estimate glomerular filtration rate in infancy, childhood and adolescence. Pediatr Clin North Am 1987;34:571-590.
14. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS: National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003;111: 1416-1421.
15. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-557.
16. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998;53:1209-1216.
17. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; for the AIPRD Study Group: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140.
18. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54:205-226.
19. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-1025.
20. Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH: Reno protection with and without blood pressure reduction. Kidney Int 2005;94:S54-S59.
21. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.